產(chǎn)品詳情
簡(jiǎn)單介紹：
重組人半胱氨酸豐富的血管生成誘導(dǎo)劑61蛋白與其它公司提供的重組蛋白不同，rHuCYR61蛋白產(chǎn)品為采用CFS的無(wú)細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來(lái)的重組蛋白，可表達(dá)出對(duì)細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時(shí)獨(dú)有的全自動(dòng)蛋白純化技術(shù)則簡(jiǎn)便高效，將蛋白純化過(guò)程中對(duì)蛋白的損傷降低到*小程度.重組人半胱氨酸豐富的血管生成誘導(dǎo)劑61蛋白（全長(zhǎng)序列）產(chǎn)品可用于Western Blot驗(yàn)證、抗體制備、蛋白檢測(cè)、ELISA等試驗(yàn)中.
詳情介紹：
重組人半胱氨酸豐富的血管生成誘導(dǎo)劑61蛋白
| Synonyms | CCN1, Cysteine-rich Angiogenic Inducer 61, GIG1, IGFBP-10 |
| Species | Human |
| Accession | O00622 |
| GeneID | 3491 |
| Source | Escherichia coli. |
| Molecular Weight | Approximately 39.4 kDa, a single non-glycosylated polypeptide chain containing 357 amino acids. |
| Quantity | 5μg/20μg/1000μg |
| AA Sequence | 重組人半胱氨酸豐富的血管生成誘導(dǎo)劑61蛋白TCPAACHCPL EAPKCAPGVG LVRDGCGCCK VCAKQLNEDC SKTQPCDHTK GLECNFGASS TALKGICRAQ SEGRPCEYNS RIYQNGESFQ PNCKHQCTCI DGAVGCIPLC PQELSLPNLG CPNPRLVKVT GQCCEEWVCD EDSIKDPMED QDGLLGKELG FDASEVELTR NNELIAVGKG SSLKRLPVFG MEPRILYNPL QGQKCIVQTT SWSQCSKTCG TGISTRVTND NPECRLVKET RICEVRPCGQ PVYSSLKKGK KCSKTKKSPE PVRFTYAGCL SVKKYRPKYC GSCVDGRCCT PQLTRTVKMR FRCEDGETFS KNVMMIQSCK CNYNCPHANE AAFPFYRLFN DIHKFRD |
| Purity | > 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重組人半胱氨酸豐富的血管生成誘導(dǎo)劑61蛋白Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine Balb/3T3 cells is less than 3.0 μg/ml, corresponding to a specific activity of > 330 IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in citrate buffer solution, 300 mM NaCl, pH 3.0. |
| Endotoxin | Less than 1 EU/μg of rHuCYR61 as determined by LAL method. |
| Reconstitution | 重組人半胱氨酸豐富的血管生成誘導(dǎo)劑61蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人半胱氨酸豐富的血管生成誘導(dǎo)劑61蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Jay P, Berge-Lefranc JL, Marsollier C, et al. 1997. Oncogene. 14:1753-7. 2. Lau LF. 2011. Cell Mol Life Sci. 68:3149-63. 3. Jun JI, Lau LF. 2011. Nat Rev Drug Discov. 10:945-63. 4. Holbourn KP, Acharya KR, Perbal B. 2008. Trends Biochem Sci. 33:461-73. |
| Background | Cysteine-rich angiogenic inducer 61 (Cyr61) encoded by the Cyr61 gene is a dynamically expressed, multifunctional matricellular protein and it is also a secreted, extracellular matrix (ECM)-associated signaling protein of the CCN family. Cyr61 plays essential roles in cardiovascular development during embryogenesis and regulates inflammation, wound healing and fibrogenesis in the *****. Aberrant CCN1 expression is associated with myriad pathologies, including various cancers and diseases associated with chronic inflammation. Mature human Cyr61 shares 93% amino acid sequence identity with mouse and rat Cyr61. Cyr61 consists of four domains. There are an IGFBP domain, a VWF type C domain, a TSP type I domain, and a cysteine knot domain. |
